dc.description.abstract | The heterocycle compounds, with their diverse functionalities, are particularly
effective in inhibiting Janus kinases (JAKs). Therefore, it is crucial to identify the
correlation between their complex structures and biological activities for the
development of new drugs for the treatment of rheumatoid arthritis (RA) and
cancer. In this study, a diverse set of 28 heterocyclic compounds selective for
JAK1 and JAK3 was employed to construct quantitative structure-activity
relationship (QSAR) models using multiple linear regression (MLR). Artificial
neural network (ANN) models were employed in the development of QSAR
models. The robustness and stability of the models were assessed through
internal and external methodologies, including the domain of applicability
(DoA). The molecular descriptors incorporated into the model exhibited a
satisfactory correlation with the receptor-ligand complex structures of JAKs
observed in X-ray crystallography, making the model interpretable and
predictive. Furthermore, pharmacophore models ADRRR and ADHRR were
designed for each JAK1 and JAK3, proving effective in discriminating between
active compounds and decoys. Both models demonstrated good performance in
identifying new compounds, with an ROC of 0.83 for the ADRRR model and an
ROC of 0.75 for the ADHRR model. Using a pharmacophore model, the most
promising compounds were selected based on their strong affinity compared to
the most active compounds in the studied series each JAK1 and JAK3. Notably,
the pharmacokinetic, physicochemical properties, and biological activities of the
selected compounds (As compounds ZINC79189223 and ZINC66252348) were
found to be consistent with their therapeutic effects in RA, owing to their nontoxic,
cholinergic nature, absence of P-glycoprotein, high gastrointestinal absorption, and ability to penetrate the blood-brain barrier. Furthermore, ADMET
properties were assessed, and molecular dynamics and MM/GBSA analysis revealed
stability in these molecules. | en_US |